Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication

Fu De Yang,1 Juan Li,1 Yun Long Tan,1 Wei Ye Liang,1 Rongzhen Zhang,1 Ning Wang,1 Wei Feng,1 Shangli Cai,2 Jian Min Zhuo,2 Li Li Zhang2 1Beijing Hui-Long-Guan Hospital, 2Department of Medical Affairs, Xian Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China Objective: The aim...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yang FD, Li J, Tan YL, Liang WY, Zhang R, Wang N, Feng W, Cai S, Zhuo JM, Zhang LL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Paliperidone ER Schizophrenia Medical Satisfaction Questionnaire Chinese Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/4be20db0d4234dc9ab21b5594bf58fd8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4be20db0d4234dc9ab21b5594bf58fd8
record_format	dspace
spelling	oai:doaj.org-article:4be20db0d4234dc9ab21b5594bf58fd82021-12-02T07:19:07ZTreatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication1178-2021https://doaj.org/article/4be20db0d4234dc9ab21b5594bf58fd82017-04-01T00:00:00Zhttps://www.dovepress.com/treatment-satisfaction-with-paliperidone-extended-release-tablets-open-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Fu De Yang,1 Juan Li,1 Yun Long Tan,1 Wei Ye Liang,1 Rongzhen Zhang,1 Ning Wang,1 Wei Feng,1 Shangli Cai,2 Jian Min Zhuo,2 Li Li Zhang2 1Beijing Hui-Long-Guan Hospital, 2Department of Medical Affairs, Xian Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China Objective: The aim of this study was to evaluate the changes in treatment satisfaction after switching to paliperidone extended-release (ER) in Chinese schizophrenia patients dissatisfied with their previous antipsychotic treatment.Methods: In this 8-week, open-label, single-arm, multicenter, prospective study, 1,693 patients dissatisfied with previous antipsychotic medication were enrolled and switched to paliperidone ER tablets (3–12 mg/d) based on clinical judgment. The primary efficacy end point was change in Medication Satisfaction Questionnaire (MSQ) score from baseline to week 8. The secondary end points included percentage of patients with MSQ score ≥4, as well as changes in Clinical Global Improvement-Severity (CGI-S) and Personal and Social Performance (PSP) scores.Results: MSQ scores increased significantly from baseline (mean [standard deviation {SD}]: 2.48 [0.55]) to week 8 (5.47 [0.89], P<0.0001; primary end point, full analysis set). The percentage of patients with MSQ score ≥4 was 95.9% at week 8, indicating that most of the patients were satisfied with their treatment. Significant (P<0.0001) improvements from baseline to week 8 were noted in CGI-S score (2.37 [1.20]) and PSP score (25.5 [15.0]). A total of 174 (10.28%) patients experienced adverse events (AEs). The most common (>10 patients) events were extrapyramidal disorder (n=84, 4.96%), poor quality sleep (n=18, 1.06%) and akathisia (n=13, 0.77%). The majority of AEs were mild to moderate in severity. No deaths occurred.Conclusion: Treatment satisfaction improved after switching to paliperidone ER from the previous antipsychotic in Chinese patients with schizophrenia. Keywords: atypical antipsychotics, open label, paliperidone extended-release, schizophrenia, medical satisfaction questionnaire, patient satisfaction, ChineseYang FDLi JTan YLLiang WYZhang RWang NFeng WCai SZhuo JMZhang LLDove Medical PressarticlePaliperidone ERSchizophreniaMedical Satisfaction QuestionnaireChineseNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 1089-1097 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Paliperidone ER Schizophrenia Medical Satisfaction Questionnaire Chinese Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Paliperidone ER Schizophrenia Medical Satisfaction Questionnaire Chinese Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Yang FD Li J Tan YL Liang WY Zhang R Wang N Feng W Cai S Zhuo JM Zhang LL Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
description	Fu De Yang,1 Juan Li,1 Yun Long Tan,1 Wei Ye Liang,1 Rongzhen Zhang,1 Ning Wang,1 Wei Feng,1 Shangli Cai,2 Jian Min Zhuo,2 Li Li Zhang2 1Beijing Hui-Long-Guan Hospital, 2Department of Medical Affairs, Xian Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China Objective: The aim of this study was to evaluate the changes in treatment satisfaction after switching to paliperidone extended-release (ER) in Chinese schizophrenia patients dissatisfied with their previous antipsychotic treatment.Methods: In this 8-week, open-label, single-arm, multicenter, prospective study, 1,693 patients dissatisfied with previous antipsychotic medication were enrolled and switched to paliperidone ER tablets (3–12 mg/d) based on clinical judgment. The primary efficacy end point was change in Medication Satisfaction Questionnaire (MSQ) score from baseline to week 8. The secondary end points included percentage of patients with MSQ score ≥4, as well as changes in Clinical Global Improvement-Severity (CGI-S) and Personal and Social Performance (PSP) scores.Results: MSQ scores increased significantly from baseline (mean [standard deviation {SD}]: 2.48 [0.55]) to week 8 (5.47 [0.89], P<0.0001; primary end point, full analysis set). The percentage of patients with MSQ score ≥4 was 95.9% at week 8, indicating that most of the patients were satisfied with their treatment. Significant (P<0.0001) improvements from baseline to week 8 were noted in CGI-S score (2.37 [1.20]) and PSP score (25.5 [15.0]). A total of 174 (10.28%) patients experienced adverse events (AEs). The most common (>10 patients) events were extrapyramidal disorder (n=84, 4.96%), poor quality sleep (n=18, 1.06%) and akathisia (n=13, 0.77%). The majority of AEs were mild to moderate in severity. No deaths occurred.Conclusion: Treatment satisfaction improved after switching to paliperidone ER from the previous antipsychotic in Chinese patients with schizophrenia. Keywords: atypical antipsychotics, open label, paliperidone extended-release, schizophrenia, medical satisfaction questionnaire, patient satisfaction, Chinese
format	article
author	Yang FD Li J Tan YL Liang WY Zhang R Wang N Feng W Cai S Zhuo JM Zhang LL
author_facet	Yang FD Li J Tan YL Liang WY Zhang R Wang N Feng W Cai S Zhuo JM Zhang LL
author_sort	Yang FD
title	Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
title_short	Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
title_full	Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
title_fullStr	Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
title_full_unstemmed	Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
title_sort	treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/4be20db0d4234dc9ab21b5594bf58fd8
work_keys_str_mv	AT yangfd treatmentsatisfactionwithpaliperidoneextendedreleasetabletsopenlabelstudyinschizophreniapatientsdissatisfiedwithpreviousantipsychoticmedication AT lij treatmentsatisfactionwithpaliperidoneextendedreleasetabletsopenlabelstudyinschizophreniapatientsdissatisfiedwithpreviousantipsychoticmedication AT tanyl treatmentsatisfactionwithpaliperidoneextendedreleasetabletsopenlabelstudyinschizophreniapatientsdissatisfiedwithpreviousantipsychoticmedication AT liangwy treatmentsatisfactionwithpaliperidoneextendedreleasetabletsopenlabelstudyinschizophreniapatientsdissatisfiedwithpreviousantipsychoticmedication AT zhangr treatmentsatisfactionwithpaliperidoneextendedreleasetabletsopenlabelstudyinschizophreniapatientsdissatisfiedwithpreviousantipsychoticmedication AT wangn treatmentsatisfactionwithpaliperidoneextendedreleasetabletsopenlabelstudyinschizophreniapatientsdissatisfiedwithpreviousantipsychoticmedication AT fengw treatmentsatisfactionwithpaliperidoneextendedreleasetabletsopenlabelstudyinschizophreniapatientsdissatisfiedwithpreviousantipsychoticmedication AT cais treatmentsatisfactionwithpaliperidoneextendedreleasetabletsopenlabelstudyinschizophreniapatientsdissatisfiedwithpreviousantipsychoticmedication AT zhuojm treatmentsatisfactionwithpaliperidoneextendedreleasetabletsopenlabelstudyinschizophreniapatientsdissatisfiedwithpreviousantipsychoticmedication AT zhangll treatmentsatisfactionwithpaliperidoneextendedreleasetabletsopenlabelstudyinschizophreniapatientsdissatisfiedwithpreviousantipsychoticmedication
_version_	1718399455379587072

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication

Ejemplares similares